Spectrum Patent-Cliff Exposure & CMS Drug Spending Portfolio

Spectrum (US): 1 reconciled FDA prescription therapies, $56.3M 2024 CMS Part D & Medicaid spend, and $1,421 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$56.3M
2024 Medicare Part D Spend$45.6M
2024 Medicaid Spend$10.7M
California HCAI SB 17 FilingsSpecialty launch notice ($1,421 intro WAC)